Merck Chairman and CEO Robert Davis joins 'Mad Money' host Jim Cramer at the JPMorgan Healthcare Conference to talk recent acquisitions, growth in its vaccine segment, opportunities in China and more.

Merck faces broader industry pressure as vaccine skeptic Robert F. Kennedy Jr. possibly next HHS secretary. Merck's shares have lost 15.3% in the past year compared with a decline of 3.9% for the ...

As Robert F. Kennedy Jr.'s confirmation hearings ... a Los Angeles personal injury law firm that is currently suing Merck, alleging the pharmaceutical giant failed to properly warn the public ...

the successful launch of WINREVAIR and strong performance of our Animal Health business," said Robert Davis, chairman and chief executive officer, Merck. Also Read: RJK Jr.'s Involvement In Merck ...

the successful launch of WINREVAIR and strong performance of our Animal Health business," said Robert M. Davis, chairman and CEO of Merck. Merck also said it has temporarily paused shipments of ...

Shares of Merck are sliding in early trading after the ... China at least through the middle of the year. Chairman and CEO Robert Davis told analysts the pause will help pare inventory and support ...

New England Patriots owner Robert Kraft is back. He is again addressing racism. He is again asking America to take a hard look at itself. He is again using America's biggest game as a vehicle to ...

Jan 18 (Reuters) - Robert F. Kennedy Jr. played an instrumental role in organizing mass litigation against drugmaker Merck over its Gardasil vaccine, a strategy that faces its first test in a Los ...

The Conference of Nigeria Political Parties (CNPP) has called on the National Assembly to take immediate steps to create five additional states in Nigeria to address regional disparities in the ...

Robert F. Kennedy Jr., President Trump’s nominee to be health secretary, would have oversight power over the vaccine’s maker, Merck, if confirmed. By Christina Jewett and Sheryl Gay Stolberg ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli ...